Delay in publication of annual accounts

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that the audit of its financial statements for the year ended 31 March 2025 (the 'Accounts') is ongoing and will not be completed by today, 30 September 2025, being the deadline under Rule 19 of the AIM Rules for Companies.

The Company continues to work with its new auditors, RPG Crouch Chapman LLP, in their first year as the Group's auditor, to ensure that the audit of the Accounts is completed as soon as possible. The Company currently anticipates that the audit will be completed, and Accounts released by mid-October 2025.

For the year ended 31 March 2025 the Company confirms on an unaudited basis that it expects to report:

• sales of £1.29m, a 61% increase year on year which reflects strong demand from existing and new customers for Fruitflow;
• an underlying operating loss of £278k (year ended 31 March 2024: £469k), an improvement of £191k year on year. The year ended 31 March 2025 included nine months of the royalty payable to dsm-firmenich at the second year rate to 31 December 2024, and three months of the royalty payable at the lower third year rate to 31 March 2025. The royalty will decrease further, and at a higher rate of year-on-year decrease, from 1 January 2026, and it will wholly cease to be payable on 31 December 2026; and
• cash at bank at 31 March 2025 of £708k, and net assets at 31 March 2025 in excess of £750k.

The Company also confirms that in the six months ended 30 September 2025:

• it has sold all of the remaining Fruitflow II SD inventory which it purchased from dsm-firmenich ('DSM') in 2023 and 2024;
• it has undertaken a new production run of Fruitflow II SD which has just been completed by the Company's outsourced supply chain partners for Fruitflow. The Company expects to receive delivery of the new batch of Fruitflow II SD in October 2025, two months later than originally planned, due in part to some significant personnel changes at an outsourced supply chain partner. The Company will pay for this new production run on delivery in October, from its existing cash resources; and
• it expects in due course to report total sales for the six months ended 30 September 2025 in excess of £350,000, and it currently expects to sell several hundred thousand pounds of Fruitflow II SD in the coming quarter ended 31 December 2025, initially supported by some existing, outstanding purchase orders.

The Company is dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2026 and beyond, in which favourable context the Company is now planning with its outsourced supply chain partners to undertake at least one further production run of Fruitflow II SD in the next twelve months.

It is currently envisaged that the Company will hold its Annual General Meeting at the offices of Allenby Capital Limited, 5th Floor, 5 St Helen's Place, London EC3A 6AB at 12:30pm on 21 November 2025.

The delay to the publication of the Accounts means that trading in the Company's ordinary shares on AIM will be temporarily suspended with effect from 7:30 AM on 1 October 2025, pending publication of the Accounts. Suspension from trading is expected to be lifted with the publication of the Accounts.